| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 32 | 2025 | 2764 | 1.760 |
Why?
|
| Receptor, ErbB-2 | 16 | 2025 | 559 | 1.320 |
Why?
|
| Physical and Rehabilitation Medicine | 2 | 2022 | 37 | 0.870 |
Why?
|
| Lymphedema | 2 | 2023 | 21 | 0.830 |
Why?
|
| Head and Neck Neoplasms | 3 | 2024 | 699 | 0.690 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2019 | 3 | 0.620 |
Why?
|
| Phyllodes Tumor | 2 | 2013 | 11 | 0.520 |
Why?
|
| Quinazolines | 11 | 2023 | 184 | 0.510 |
Why?
|
| Trastuzumab | 11 | 2025 | 154 | 0.500 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2025 | 821 | 0.500 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 1354 | 0.480 |
Why?
|
| Neoadjuvant Therapy | 9 | 2023 | 404 | 0.480 |
Why?
|
| Receptors, Estrogen | 11 | 2022 | 828 | 0.430 |
Why?
|
| Ultrasonography, Mammary | 1 | 2013 | 33 | 0.420 |
Why?
|
| Neoplasms | 5 | 2023 | 3027 | 0.420 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 32 | 0.410 |
Why?
|
| Biomarkers, Tumor | 9 | 2023 | 1720 | 0.380 |
Why?
|
| Osteosarcoma | 1 | 2013 | 263 | 0.340 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2016 | 271 | 0.340 |
Why?
|
| Molecular Targeted Therapy | 7 | 2025 | 407 | 0.340 |
Why?
|
| Ki-67 Antigen | 3 | 2022 | 119 | 0.320 |
Why?
|
| Tamoxifen | 5 | 2016 | 377 | 0.310 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2025 | 267 | 0.300 |
Why?
|
| Tumor Microenvironment | 3 | 2025 | 690 | 0.290 |
Why?
|
| Immunohistochemistry | 4 | 2022 | 1761 | 0.260 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2017 | 262 | 0.220 |
Why?
|
| STAT5 Transcription Factor | 2 | 2022 | 91 | 0.220 |
Why?
|
| Female | 38 | 2025 | 71659 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2018 | 1006 | 0.210 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 132 | 0.210 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 1850 | 0.200 |
Why?
|
| Humans | 43 | 2025 | 133932 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2020 | 554 | 0.190 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 82 | 0.190 |
Why?
|
| Deglutition Disorders | 1 | 2024 | 147 | 0.190 |
Why?
|
| Quinolines | 1 | 2022 | 112 | 0.180 |
Why?
|
| Human Trafficking | 1 | 2022 | 60 | 0.180 |
Why?
|
| Genes, erbB-2 | 3 | 2011 | 38 | 0.180 |
Why?
|
| Cell Line, Tumor | 8 | 2018 | 3751 | 0.180 |
Why?
|
| Gene Editing | 1 | 2023 | 212 | 0.170 |
Why?
|
| Physical Therapy Modalities | 1 | 2021 | 61 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 4 | 2011 | 1069 | 0.160 |
Why?
|
| Pathology, Clinical | 1 | 2019 | 26 | 0.160 |
Why?
|
| Gene Expression | 3 | 2020 | 1614 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 137 | 0.150 |
Why?
|
| Signal Transduction | 9 | 2025 | 4900 | 0.150 |
Why?
|
| Optical Imaging | 1 | 2019 | 74 | 0.150 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 1 | 2018 | 19 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 440 | 0.140 |
Why?
|
| Middle Aged | 13 | 2020 | 29394 | 0.140 |
Why?
|
| Tissue Array Analysis | 2 | 2015 | 143 | 0.130 |
Why?
|
| Transcriptome | 3 | 2025 | 1127 | 0.130 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2014 | 101 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 49 | 0.130 |
Why?
|
| Estradiol | 2 | 2016 | 551 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 2122 | 0.130 |
Why?
|
| Treatment Outcome | 8 | 2023 | 13011 | 0.120 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 111 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 494 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 221 | 0.120 |
Why?
|
| Adult | 14 | 2022 | 31946 | 0.120 |
Why?
|
| Mice, Nude | 5 | 2018 | 777 | 0.120 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 1977 | 0.110 |
Why?
|
| Mice | 13 | 2023 | 18911 | 0.110 |
Why?
|
| Quality of Life | 2 | 2024 | 2134 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 78 | 0.110 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 112 | 0.110 |
Why?
|
| Granulomatous Mastitis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Hospitals, County | 1 | 2013 | 24 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 66 | 0.100 |
Why?
|
| Hospitals, Urban | 1 | 2013 | 99 | 0.100 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 4776 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 474 | 0.100 |
Why?
|
| Sirolimus | 1 | 2014 | 253 | 0.100 |
Why?
|
| Animals | 15 | 2023 | 36398 | 0.100 |
Why?
|
| Fibroadenoma | 1 | 2012 | 10 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2025 | 611 | 0.100 |
Why?
|
| ErbB Receptors | 3 | 2011 | 303 | 0.100 |
Why?
|
| Oncogenes | 2 | 2013 | 179 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2022 | 644 | 0.090 |
Why?
|
| Atrioventricular Node | 1 | 2011 | 17 | 0.090 |
Why?
|
| Death, Sudden | 1 | 2011 | 50 | 0.090 |
Why?
|
| Lymphoma, T-Cell | 1 | 2011 | 65 | 0.090 |
Why?
|
| Heart Neoplasms | 1 | 2011 | 106 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 746 | 0.080 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2009 | 80 | 0.080 |
Why?
|
| Fibroblasts | 1 | 2014 | 922 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 5173 | 0.080 |
Why?
|
| Models, Biological | 1 | 2014 | 1533 | 0.070 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2008 | 88 | 0.070 |
Why?
|
| Lentivirus | 1 | 2008 | 86 | 0.070 |
Why?
|
| Prognosis | 4 | 2020 | 5074 | 0.070 |
Why?
|
| Smad5 Protein | 1 | 2007 | 22 | 0.070 |
Why?
|
| Smad1 Protein | 1 | 2007 | 23 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1386 | 0.070 |
Why?
|
| Exercise | 2 | 2024 | 877 | 0.070 |
Why?
|
| Breast | 2 | 2022 | 218 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2009 | 688 | 0.070 |
Why?
|
| Adnexa Uteri | 1 | 2006 | 9 | 0.070 |
Why?
|
| Jejunal Diseases | 1 | 2006 | 15 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2006 | 15 | 0.070 |
Why?
|
| Ovarian Diseases | 1 | 2006 | 28 | 0.060 |
Why?
|
| Antigens, Differentiation | 1 | 2006 | 68 | 0.060 |
Why?
|
| Fistula | 1 | 2006 | 54 | 0.060 |
Why?
|
| Antibodies, Blocking | 1 | 2006 | 63 | 0.060 |
Why?
|
| Aged | 8 | 2020 | 21730 | 0.060 |
Why?
|
| Testis | 1 | 2007 | 426 | 0.060 |
Why?
|
| MCF-7 Cells | 2 | 2016 | 232 | 0.060 |
Why?
|
| Ovary | 1 | 2007 | 384 | 0.060 |
Why?
|
| Biopsy | 2 | 2022 | 1304 | 0.060 |
Why?
|
| Mutation | 5 | 2018 | 6297 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2020 | 1596 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2008 | 970 | 0.060 |
Why?
|
| Cell Survival | 2 | 2018 | 891 | 0.050 |
Why?
|
| Mammary Glands, Animal | 2 | 2022 | 477 | 0.050 |
Why?
|
| Pelvic Neoplasms | 1 | 2003 | 24 | 0.050 |
Why?
|
| Recombinational DNA Repair | 1 | 2023 | 19 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 103 | 0.050 |
Why?
|
| Receptors, Progesterone | 3 | 2015 | 897 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 87 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 3054 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 7204 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2024 | 180 | 0.050 |
Why?
|
| Survivors | 1 | 2023 | 360 | 0.040 |
Why?
|
| Macrophages | 1 | 2025 | 704 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 401 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2023 | 292 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 453 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 83 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 77 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2025 | 1814 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2022 | 621 | 0.040 |
Why?
|
| Cell Division | 2 | 2013 | 774 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2017 | 2539 | 0.040 |
Why?
|
| Melanoma | 1 | 2006 | 975 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 1418 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 907 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 312 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2022 | 941 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2013 | 1240 | 0.030 |
Why?
|
| Male | 4 | 2019 | 65882 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 142 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 679 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 239 | 0.030 |
Why?
|
| Apoptosis | 2 | 2013 | 1931 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 1911 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 183 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 714 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 199 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1702 | 0.030 |
Why?
|
| HIV Infections | 1 | 2006 | 2067 | 0.030 |
Why?
|
| Doxycycline | 1 | 2014 | 121 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2014 | 213 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 395 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 351 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 318 | 0.020 |
Why?
|
| Mammography | 1 | 2013 | 132 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2013 | 3980 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 155 | 0.020 |
Why?
|
| Steroids | 1 | 2013 | 210 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 6588 | 0.020 |
Why?
|
| Triazoles | 1 | 2013 | 142 | 0.020 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2012 | 34 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2008 | 3167 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 613 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 456 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 508 | 0.020 |
Why?
|
| Forensic Pathology | 1 | 2011 | 8 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 755 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 220 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2013 | 364 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 1789 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 240 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 905 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 399 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5505 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 50 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 372 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 1471 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 667 | 0.020 |
Why?
|
| Keratin-9 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Alpharetrovirus | 1 | 2008 | 5 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 1002 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2008 | 96 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2008 | 99 | 0.020 |
Why?
|
| Smad8 Protein | 1 | 2007 | 6 | 0.020 |
Why?
|
| Sertoli Cell Tumor | 1 | 2007 | 8 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 235 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 282 | 0.020 |
Why?
|
| Granulosa Cell Tumor | 1 | 2007 | 39 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 971 | 0.020 |
Why?
|
| HIV | 1 | 2008 | 195 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 2239 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 125 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1139 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 275 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 2007 | 135 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2295 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2006 | 68 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2006 | 188 | 0.020 |
Why?
|
| Ascites | 1 | 2006 | 99 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2006 | 78 | 0.020 |
Why?
|
| Myocardium | 1 | 2011 | 1046 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 836 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 1483 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2006 | 250 | 0.020 |
Why?
|
| Fertility | 1 | 2007 | 267 | 0.010 |
Why?
|
| Biomarkers | 1 | 2015 | 3423 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 9887 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2006 | 207 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2006 | 191 | 0.010 |
Why?
|
| Estrogens | 1 | 2007 | 521 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2007 | 809 | 0.010 |
Why?
|
| Survival Rate | 1 | 2009 | 2207 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 17481 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2006 | 452 | 0.010 |
Why?
|
| Obesity, Morbid | 1 | 2006 | 212 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 754 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 4547 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 2527 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2003 | 313 | 0.010 |
Why?
|
| Child | 1 | 2022 | 25739 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2520 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 447 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 1315 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 7523 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 3695 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 2196 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 1410 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 11087 | 0.010 |
Why?
|